CDK
CDK (Cyclin-Dependent Kinase) inhibitors are compounds that block the activity of CDKs, a group of protein kinases that regulate the cell cycle, transcription, and other cellular processes. CDKs are activated by binding to cyclins, and their activity is crucial for the progression of cells through different phases of the cell cycle. Inhibiting CDKs can halt cell division, leading to cell cycle arrest and apoptosis, particularly in cancer cells where CDKs are often dysregulated. CDK inhibitors are widely used in cancer research and have therapeutic potential in treating various cancers. At CymitQuimica, we provide a comprehensive selection of high-quality CDK inhibitors to support your research in cell cycle control, cancer, and therapeutic development.
Found 546 products of "CDK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
CGP60474
CAS:CGP60474 is an inhibitor of VEGFR-2 (IC50 = 84 nM) and an inhibitor of ATP-competitive PKC.Formula:C18H18ClN5OPurity:98.81%Color and Shape:SolidMolecular weight:355.82Ref: TM-T14943
1mg34.00€2mg46.00€5mg71.00€10mg92.00€25mg177.00€50mg314.00€100mg518.00€1mL*10mM (DMSO)78.00€CDK9-IN-15
CAS:CDK9-IN-15: potent CDK9 inhibitor, blocks P-TEFb phosphorylation, inhibits transcription, reduces mRNA, induces tumor cell apoptosis.Formula:C16H11N3OSPurity:99.32%Color and Shape:SolidMolecular weight:293.34Ref: TM-T60619
5mg46.00€10mg71.00€25mg126.00€50mg180.00€100mg260.00€200mg364.00€1mL*10mM (DMSO)44.00€Atuveciclib S-Enantiomer
CAS:Atuveciclib S-Enantiomer is a (S)-form of BAY-1143572; a potent, selective CDK9 inhibitor with an IC50 of 16 nM.Formula:C18H18FN5O2SPurity:98%Color and Shape:SolidMolecular weight:387.43CDK2-IN-13
CAS:CDK2-IN-13: Potent CDK2 inhibitor, arrests cell cycle, induces apoptosis, IC50=12 µM, used in cancer research.Formula:C13H12ClN5Color and Shape:SoildMolecular weight:273.72NSC 625987
CAS:NSC 625987, Selective CDK4 inhibitor (IC50=0.2 μM), >500-fold selectivity over CDK2, used for p16-associated tumor studies.Formula:C15H13NO2SPurity:98%Color and Shape:SolidMolecular weight:271.33Ref: TM-T23092
1mg63.00€2mg105.00€5mg137.00€10mgTo inquire25mgTo inquire50mg595.00€100mg893.00€1mL*10mM (DMSO)To inquireARN22089
CAS:ARN22089 is an oral active CDC42 GTPase interaction inhibitor that blocks tumour growth in BRAF mutant mouse melanoma models and PDXs in vivo.Formula:C23H27N5Purity:98.37%Color and Shape:SolidMolecular weight:373.49Ref: TM-T85727
1mg109.00€5mg260.00€10mg385.00€25mg647.00€50mg964.00€100mg1,431.00€200mg1,963.00€1mL*10mM (DMSO)286.00€Cdc7-IN-4
CAS:Cdc7-IN-4 is a potent inhibitor of Cdc7 kinase.Formula:C22H24F3N5O4Purity:98%Color and Shape:SolidMolecular weight:479.45BAY-958
CAS:BAY-958 is a potent and selective inhibitor of PTEFb/CDK9.Formula:C17H16FN5O3SPurity:98%Color and Shape:SolidMolecular weight:389.4TP1287
CAS:TP-1287 is an oral phosphate prodrug of the CDK9 inhibitor, alvocidib.Formula:C21H21ClNO8PColor and Shape:SolidMolecular weight:481.82Aloisine A
CAS:Aloisine A, a CDK/GSK-3 inhibitor with IC50: Cdk1/B-150nM, Cdk2/A-120nM, Cdk2/E-400nM, Cdk5/25-200nM, Cdk5/35-160nM, GSK-3α-500nM, GSK-3β-650nM, JNK-3-10μM.Formula:C16H17N3OPurity:98%Color and Shape:SolidMolecular weight:267.33CLK1-IN-2
CLK1-IN-2: Metabolically stable, Clk1-selective inhibitor; IC50=1.7nM; useful in tumor, Duchenne MD, HIV-1, influenza research.Formula:C16H12Cl2N2O2SColor and Shape:SolidMolecular weight:367.25CDK4/6-IN-8
CAS:CDK4/6-IN-8 (Compound 7p) is a selective inhibitor of CDK4 (IC50=5.01 nM) and CDK6 (IC50=3.97 nM).Formula:C18H18N6O5Color and Shape:SolidMolecular weight:398.37NSC 693868
CAS:CDKs and GSK-3 inhibitorFormula:C9H7N5Purity:98%Color and Shape:SolidMolecular weight:185.19(E/Z)-BIO-acetoxime
CAS:(E/Z)-BIO-acetoxime: potent GSK-3 α/β inhibitor; IC50: GSK-3α/β 10nM, CDK5/p25 2.4μM, CDK2/A 4.3μM, CDK1/B 63μM.Formula:C18H12BrN3O3Color and Shape:SolidMolecular weight:398.21MFH290
CAS:MFH290 is a selective CDK12/13 inhibitor, covalently bonding with CDK12 Cys-1039, blocks Pol II CTD phosphorylation, and enhances olaparib's efficacy.Formula:C26H31N5O3S2Color and Shape:SolidMolecular weight:525.69RP-106
CAS:RP-106 is an ATP-competitive inhibitor of CDK5/p25, CDK1/cyclin B, and GSK-3.Formula:C17H19N3OPurity:98%Color and Shape:SolidMolecular weight:281.35CDK8-IN-10
CAS:CDK8-IN-10 is a selective and potent inhibitor of cell cycle protein-dependent kinase (CDK8) (IC50: 8.25 nM) that can be used to study cancer.Formula:C25H15ClF3N5O3Color and Shape:SolidMolecular weight:525.87CDK4/6-IN-12
CAS:CDK4/6-IN-12 inhibits CDK4/6 with IC50s of 592.3 nM & 3090 nM, useful in cancer research.Formula:C12H10N6Color and Shape:SolidMolecular weight:238.25CCT068127
CAS:CCT068127 is a potent CDK2 and CDK9 inhibitor.Formula:C19H27N7OColor and Shape:SolidMolecular weight:369.46(S)-CR8
CAS:(S)-CR8 is an effective second-generation cyclin-dependent kinase inhibitor.Formula:C24H29N7OColor and Shape:SolidMolecular weight:431.53(S)-LY3177833 hydrate
CAS:(S)-LY3177833 ((S)-Example 2) hydrate, an orally active CDC7 kinase inhibitor, exhibits extensive in vitro anticancer efficacy.Formula:C16H14FN5O2Color and Shape:SolidMolecular weight:327.31EGFR/HER2/CDK9-IN-2
CAS:EGFR/HER2/CDK9-IN-2 inhibits EGFR, HER2, CDK9 with IC50s: 145.35, 129.07, 117.13 nM; strong antitumor effects.Formula:C23H20N4O5S2Color and Shape:SolidMolecular weight:496.56Cdc7-IN-9
CAS:Cdc7-IN-9 can be used for the research of cancer which is a potent inhibitor of Cdc7 [1].Formula:C15H17N5OSColor and Shape:SolidMolecular weight:315.39Cdc7-IN-14
CAS:Cdc7-IN-14 (compound 82) is a potent CDC7 inhibitor with an IC50 < 1 nM, promising for cancer research.Formula:C18H20N4O2SColor and Shape:SolidMolecular weight:356.44KH-CB19
CAS:KH-CB19 is an effective and highly specific inhibitor of the CDC2-like kinase isoforms 1 and 4 (CLK1/CLK4).Formula:C15H13Cl2N3O2Color and Shape:SolidMolecular weight:338.19Ref: TM-T15657
2mgTo inquire5mgTo inquire25mgTo inquire50mgTo inquire100mgTo inquire1mL*10mM (DMSO)To inquireCDK8-IN-6
CAS:CDK8-IN-6 (compound 9) is a potent inhibitor of cyclin-dependent kinase 8 (CDK8) (Kd: 13 nM), CDK8-IN-6 showed potential research value in AML cancers.Formula:C26H37ClN2Color and Shape:SolidMolecular weight:413.04Ipivivint
CAS:Ipivivint: orally active, potent CLK inhibitor; hinders CLK1, CLK2, & CLK3; curbs Wnt signaling & SRSF phosphorylation for cancer research.Formula:C26H21FN8Color and Shape:SolidMolecular weight:464.5FN-1501-propionic acid
CAS:FN-1501-propionic acid, a CDK2/9 ligand, in conjunction with a CRBN ligand, has been utilized in the design of a PROTAC CDK2/9 degrader.Formula:C25H27N9O4Purity:98%Color and Shape:SolidMolecular weight:517.54Cdc7-IN-3
CAS:Cdc7-IN-3 is a potent inhibitor of Cdc7 kinase.Formula:C20H22N4O5Purity:98%Color and Shape:SolidMolecular weight:398.41JTK-101
CAS:JTK-101 is a potent and selective Tat-dependent HIV-1 replication inhibitor.Formula:C25H23N3O3Color and Shape:SolidMolecular weight:413.47Ulecaciclib
CAS:Ulecaciclib: oral, BBB-permeable CDK inhibitor; favorable pharmacokinetics; ki: 0.62 μM (CDK2/A), 3 nM (CDK6/D3), 0.2 nM (CDK4/D1), 0.63 μM (CDK7/H).Formula:C25H33FN8SColor and Shape:SolidMolecular weight:496.65Cdc7-IN-13
CAS:Cdc7-IN-13 (compound 84) is a highly potent CDC7 inhibitor, exhibiting an IC50 value of <1 nM. This compound holds promise for cancer research [1].Formula:C18H20N4O2SColor and Shape:SolidMolecular weight:356.44CDK4/6-IN-9
CAS:CDK4/6-IN-9 selectively inhibits CDK4/6 (IC50: 905 nM); potential for MM research.Formula:C22H23FN8Color and Shape:SolidMolecular weight:418.47CDK1-IN-1
CAS:CDK1-IN-7 inhibits CDK1 at 161.2 nM, triggers p53-dependent apoptosis, and selectively targets tumor growth.Formula:C27H23N5O3Color and Shape:SolidMolecular weight:465.5Indirubin-5-sulfonate
CAS:Indirubin-5-sulfonate inhibits GSK-3β & CDKs with IC50: 55/35/150/300/65 nM for CDK1/B, 2/A&E, 4/D1, 5/p35.Formula:C16H10N2O5SPurity:98%Color and Shape:SolidMolecular weight:342.33CDK7-IN-8
CAS:CDK7-IN-8 is a potent inhibitor of CDK7 (IC50: 54.29 nM) and exhibits inhibitory activity against several cancer cells and in vivo tumor models.Formula:C25H38N8O3Color and Shape:SolidMolecular weight:498.62FLT3/CDK4-IN-1
CAS:FLT3/CDK4-IN-1: Oral FLT3 (7 nM IC50) & CDK4 (11 nM IC50) inhibitor with strong in vivo anti-cancer properties.Formula:C25H28F2N8Color and Shape:SolidMolecular weight:478.54CDK7-IN-20
CDK7-IN-20: potent, irreversible CDK7 inhibitor, IC50 of 4nM, 206x selectivity vs. other CDKs, potential for ADPKD study.Formula:C30H26N6O3Color and Shape:SolidMolecular weight:518.57CDK7-IN-13
CAS:CDK7-IN-13 (compound 1) is an effective CDK7 inhibitor for investigating cancers associated with transcriptional dysregulation.Formula:C20H23F3N6OSPurity:99.22%Color and Shape:SolidMolecular weight:452.5Indirubin-3'-monoxime-5-sulphonic acid
CAS:Indirubin-3'-monoxime-5-sulphonic acid is a potent and selective inhibitor of GSK-3β, CDK5, and CDK1 with IC50s of 80nM,5 nM, and 7 nM, respectively.Formula:C16H11N3O5SPurity:98%Color and Shape:SolidMolecular weight:357.34BSJ-01-175
CAS:BSJ-01-175: Selective, potent covalent inhibitor of CDK12/13, targets cancer cells, inhibits phosphorylated RNA polymerase II, downregulates CDK12 genes.Formula:C30H33ClN6O2Color and Shape:SolidMolecular weight:545.08MDK6204
CAS:MDK6204 is a selective inhibitor of CLK1 and CLK2.Formula:C20H20N6OPurity:98%Color and Shape:SolidMolecular weight:360.41XIE18-6
CAS:XIE18-6 is a novel INK4C inhibitor that blocks p18 activity and promotes ex vivo expansion of human and murine hematopoietic stem cells.Formula:C18H15NO6SPurity:99.712%Color and Shape:SolidMolecular weight:373.38CDK4/6-IN-14
CAS:CDK4/6-IN-14: potent CDK4/6 inhibitor, IC50s 10/16 nM, >60-fold selectivity over CDKs 1/2/7/9, selective across 205 kinases.Formula:C24H27ClFN7OColor and Shape:SolidMolecular weight:483.97EGFR/HER2/CDK9-IN-1
CAS:EGFR/HER2/CDK9-IN-1 is a potent inhibitor (IC50: EGFR 90.17 nM, HER2 131.39 nM, CDK9 67.04 nM) with notable anti-tumor activity.Formula:C23H21N3O3S2Color and Shape:SolidMolecular weight:451.56CDK7-IN-2
CAS:CDK7-IN-2 inhibits CDK7, essential for RNA polymerase II activation and cell cycle control, with cancer research potential.Formula:C26H39N7O3Color and Shape:SolidMolecular weight:497.63CDK4/6-IN-7
CAS:CDK4/6-IN-7 is an oral, potent CDK4/6 inhibitor with IC50s of 1.58/4.09 nM, crucial for breast cancer studies.Formula:C18H18ClN5O3Color and Shape:SolidMolecular weight:387.82CDK7-IN-12
CAS:CDK7-IN-12 inhibits CDK7 to control transcription and cell cycle, halting tumor growth in vitro/vivo with cancer research potential.Formula:C20H19F3N6Color and Shape:SolidMolecular weight:400.4Crozbaciclib fumarate
CAS:Crozbaciclib fumarate is a CDK4/6 inhibitor with IC 50 s of 3 and 1 nM, respectively.Formula:C32H34F2N6O4Color and Shape:SolidMolecular weight:604.65EGFR/CDK2-IN-1
CAS:EGFR/CDK2-IN-1, an inhibitor of both EGFR and CDK2, demonstrates effective cytotoxicity towards MCF7 and HepG2 cells, suggesting its potential application inFormula:C19H12BrClO2Color and Shape:SolidMolecular weight:387.65
